Anidulafungin - State of affairs from a clinical perspective

Mycoses

Volumn 50, Issue SUPPL. 1, 2007, Pages 38-43

  Vehreschild, Jörg J ^a   Kümmerle, Tim ^a   Karthaus, Meinolf ^b   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

Anidulafungin; Antifungal agents; Aspergillosis; Candidiasis; Drug therapy; Invasive fungal infection; Lipoproteins; Therapeutic use

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; GLUCOCORTICOID; TACROLIMUS; VORICONAZOLE;

ABDOMINAL ABSCESS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANDIDIASIS; FUNGICIDAL ACTIVITY; HUMAN; NONHUMAN; PEDIATRICS; PERITONITIS; PRIORITY JOURNAL; REVIEW; SPECIES INVASION;

ANIMALIA; ASPERGILLUS; CANDIDA; FUNGI;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ECHINOCANDINS; HUMANS; RABBITS;

EID: 33947648925     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01378.x     Document Type: Review

References (38)

1. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004; 54: 1051-6.
2. Keating G, Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003; 63: 2235-63.
3. Diekema DJ, Boyken L, Hollis RJ et al. Anidulafungin Activity Against Invasive Clinical Isolates of Candida: Relationship to Fluconazole Susceptibility. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006 (abstract M-362).
4. Vazquez JA. Invasive oesophageal candidiasis: current and developing treatment options. Drugs 2003; 63: 971-89.
5. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-5.
6. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother 2004; 48: 1912-5.
7. Bartlett MS, Current WL, Goheen MP et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996; 40: 1811-6.
8. Insa R, Peláez T, Goyanes M et al. In Vitro Activity of Anidulafungin and Caspofungin in Candida Species: There is a Significant Correlation Between the Activity of Both Candins? Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006 (abstract M-1592).
9. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
10. Nagappan V, Riederer K, Big C, Vazquez JA. In Vitro Activity of Echinocandins against Different Strains of Candida parapsilosis. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006 (abstract M-1581).
11. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-4.
12. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8.
13. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006; 50: 3926-8.
14. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
15. ClinicalTrials.gov. 2006. Available at: http://www.clinicaltrials. gov, accessed on 6 November 2006.
16. Dowell JA, Schranz J, Stogniew M, Krause D, Henkel T. Assessment of the Pharmacokinetics of Anidulafungin in Patients with Invasive Aspergillosis Receiving Concomitant Liposomal Amphotericin. European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004.
17. Dowell JA, Stogniew M, Krause D, Henkel T. Anidulafungin (ANID) Pharmacokinetic (PK)/Pharmacodynamic (PD) Correlation: Treatment of Esophageal Candidiasis (EC). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003 (abstract A-1578 and poster).
18. Dowell JA, Pu F, Lee J, Stogniew M, Krause D, Henkel T. A Clinical Mass Balance Study of Anidulafungin (ANID) Showing Complete Fecal Elimination. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003 (Abstract A-1576 and poster).
19. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590-8.
20. Thye D, Marbury T, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: Pharmacokinetics in Subjects Receiving Hemodialysis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2002 (Abstract no. A-1390).
21. Thye D, Kilfoil T, White RJ, Lasseter K. Anidulafungin: Pharmacokinetics in Subjects with Mild and Moderate Hepatic Impairment. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001 (Abstract A-34 and poster).
22. Thye D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: Pharmacokinetics (PK) in Subjects with Severe Hepatic Impairment (HI). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2002 (Abstract no. A-1390).
23. Kelley K, Chapman S, Cleary J. Digestion of Echinocandins. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006.
24. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-33.
25. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45: 1373-82.
26. Dowell JA, Schranz J, Buckwalter M, Stogniew M, Krause D. Tacrolimus Pharmacokinetics are not Affected by Concomitant Anidulafungin. European Congress of Clinical Microbiology and Infectious Diseases, Kopenhagen, 2005.
27. Stogniew M, Dowell JA, Krause D, Henkel T. Population Pharmacokinetics Confirms Absence of Anidulafungin Drug-drug Interactions. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004 (abstract no. 1035).
28. Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob Agents Chemother 2000; 44: 378-81.
29. Krause DS, Reinhardt J, Vazquez JA et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48: 2021-4.
30. Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50: 632-8.
31. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-8.
32. Petraitis V, Petratiene R, Hope W et al. Combination Therapy of Voriconazole and Anidulafungin Improves Outcome of Experimental Pulmonary Aspergillosis. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006 (abstract M-882).
33. Gumbo T, Drusano GL, Liu W et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3695-700.
34. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-5.
35. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9.
36. Pfaller MA, Diekema DJ, Boyken L et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 2005; 49: 4795-7.
37. Reboli A, Rotstein C, Pappas PG, Schranz J, Krause D, Walsh TJ. Anidulafungin vs. Fluconazole for Treatment of Candidemia and Invasive Candidiasis (C/IC). Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005.
38. Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a Phase 1 Study to Identify the Maximum Tolerated Dose in Healthy Volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001 (abstract A-36).